Irreversible Electroporation (IRE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
← catalyst calendarNCT07640776 · readout ≤ 499 d
Sponsored by Angiodynamics, Inc. (industry) · ANGO — their whole pipeline →.
Phase
Not applicable
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
40estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
Intervention
- Device: Irreversible Electroporation
Primary outcomes
what the primary-completion date above is the date OFIncidence and severity of device-related adverse events (AEs) through 6 months post-procedure
measured From treatment through 6 months post-procedure
Mean change in International Prostate Symptom Score (IPSS) from baseline to 6 months post-procedure
measured From baseline through 6 months post-procedure
Permalink · ANGO's whole pipeline · Catalyst calendar · Every registered study · What changed